Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Authors = Phatcharin Khamplong

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
12 pages, 1816 KiB  
Article
KERRA, Mixed Medicinal Plant Extracts, Inhibits SARS-CoV-2 Targets Enzymes and Feline Coronavirus
by Supaphorn Seetaha, Phatcharin Khamplong, Panatda Wanaragthai, Thitinan Aiebchun, Siriluk Ratanabunyong, Sucheewin Krobthong, Yodying Yingchutrakul, Jatuporn Rattanasrisomporn and Kiattawee Choowongkomon
COVID 2022, 2(5), 621-632; https://doi.org/10.3390/covid2050046 - 16 May 2022
Cited by 9 | Viewed by 15231
Abstract
The COVID-19 pandemic affects all parameters, especially healthcare professionals, drugs and medical supplies. The KERRA is a mixed medicinal plant capsule that is used for the treatment of patients with high fever, with food and drug administration approved by FDA Thailand. Recently, KERRA [...] Read more.
The COVID-19 pandemic affects all parameters, especially healthcare professionals, drugs and medical supplies. The KERRA is a mixed medicinal plant capsule that is used for the treatment of patients with high fever, with food and drug administration approved by FDA Thailand. Recently, KERRA showed induced quicker recovery for COVID-19 patients. Therefore, it is possible that some ingredients in KERRA could inhibit SARS-CoV-2. In this study, two important replication-related enzymes in SARS-CoV-2, a main protease and an RNA-dependent RNA polymerase (RdRp), were used to study the effect of KERRA. The results showed that KERRA inhibited the SARS-CoV-2 main protease and SARS-CoV-2 RdRp with IC50 values of 49.91 ± 1.75 ng/mL and 36.23 ± 5.23 µg/mL, respectively. KERRA displayed no cytotoxic activity on macrophage cells at concentrations lower than 1 mg/mL and exhibited anti-inflammatory activity. Additionally, KERRA was used against a feline coronavirus (feline infectious peritonitis (FIP)) infection with an EC50 value of 134.3 μg/mL. This study supports the potential use of KERRA as a candidate drug for COVID-19. Full article
Show Figures

Graphical abstract

Back to TopTop